The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
S | Sensory organs | |
2
|
S01 | Ophthalmologicals | |
3
|
S01E | Antiglaucoma preparations and miotics | |
4
|
S01EE | Prostaglandin analogues | |
5
|
S01EE06 |
| Active Ingredient |
|---|
|
Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss. |
| Document | Type | Information Source | |
|---|---|---|---|
| VYZULTA Οphthalmic solution | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.